Reuters logo
BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.86
2017年11月7日 / 晚上9点04分 / 12 天前

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.86

Nov 7 (Reuters) - Arena Pharmaceuticals Inc:

* Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results

* Q3 loss per share $0.86

* Q3 revenue $7.9 million

* Q3 revenue view $5.5 million -- Thomson Reuters I/B/E/S

* Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S

* Arena Pharmaceuticals Inc - ‍expect to complete full enrollment for etrasimod phase 2 study in ulcerative colitis this week​

* Arena Pharmaceuticals Inc - ‍initiated etrasimod phase 2 study in primary biliary cholangitis​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below